ASHP Strongly Opposes Proposed Changes to Medicare Reimbursement
July 26th 2017Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation’s safety net hospitals, according to pharmacy group ASHP.
Read More
Baricitinib for RA NDA Application Delayed at Least 18 Months
July 25th 2017Officials with the FDA are requesting a new clinical study before Eli Lilly and Incyte Corporation can resubmit for a new drug application (NDA) for baricitinib, a once-daily oral medication for moderate-to-severe rheumatoid arthritis treatment.
Read More